Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours

Purpose: There is an increasing interest in the role of sex and gender in cancer pa-tients. The impact of sex differences in oncological systemic therapies is still unknown, and there is a lack of evidence specially in uncommon neoplasms like neuroendocrine tumours (NET). In the present study, we co...

Descripción completa

Detalles Bibliográficos
Autores: Hernando, Jorge, Roca Herrera, Maria, García Álvarez, Alejandro, Raymond, Eric, Ruszniewski, Philippe, Kulke, Matthew H., Grande, Enrique, Garcia Carbonero, Rocio, Castellano, Daniel, Salazar, Ramón, Ibrahim, Toni, Teulé Vega, Àlex, Alonso, Vicente, Fazio, Nicola, Valle, Juan W., Tafuto, Salvatore, Carmona, Ana, Navarro, Victor, Capdevila, Jaume
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/201424
Acceso en línea:https://hdl.handle.net/2445/201424
Access Level:acceso abierto
Palabra clave:Neuroendocrinologia
Tumors
Factors sexuals en les malalties
Neuroendocrinology
Sex factors in disease
id ES_a9ec901f1b31ca34930e2bfbcfcb1318
oai_identifier_str oai:diposit.ub.edu:2445/201424
network_acronym_str ES
network_name_str España
repository_id_str
spelling Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumoursHernando, JorgeRoca Herrera, MariaGarcía Álvarez, AlejandroRaymond, EricRuszniewski, PhilippeKulke, Matthew H.Grande, EnriqueGarcia Carbonero, RocioCastellano, DanielSalazar, RamónIbrahim, ToniTeulé Vega, ÀlexAlonso, VicenteFazio, NicolaValle, Juan W.Tafuto, SalvatoreCarmona, AnaNavarro, VictorCapdevila, JaumeNeuroendocrinologiaTumorsFactors sexuals en les malaltiesNeuroendocrinologyTumorsSex factors in diseasePurpose: There is an increasing interest in the role of sex and gender in cancer pa-tients. The impact of sex differences in oncological systemic therapies is still unknown, and there is a lack of evidence specially in uncommon neoplasms like neuroendocrine tumours (NET). In the present study, we combine the differential toxicities by sex in five published clinical trials with multikinase inhibitors (MKI) in gastroenteropancreatic (GEP) NET.Methods: We performed a pooled univariate analysis of reported toxicity in patients treated in five phase 2 and phase 3 clinical trials with MKI in the GEP NET setting: sunitinib (SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT). Differential toxicities between male and female patients were evaluated considering relationship with study drug and different weights of each trial by random effect adjustment.Results: We found nine toxicities which were more frequent in female patients (leukopenia, alopecia, vomiting, headache, bleeding, nausea, dysgeusia, neutrophil count decreased and dry mouth) and two toxicities being more frequent in male patients (Anal Symptoms and Insomnia). Asthenia and diarrhoea were the only severe (Grade 3-4) toxicities more frequent in female pa-tients.Conclusions: Sex-related differences in toxicity with the MKI treatment require targeted in-formation and individualised management of patients with NET. Differential reporting of toxicity should be promoted when clinical trials are published.(c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY -NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Elsevier BV2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/201424Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del document publicat a: https://doi.org/10.1016/j.ejca.2023.04.013European Journal of Cancer, 2023, vol. 188, p. 39-48https://doi.org/10.1016/j.ejca.2023.04.013cc by-nc-nd (c) Hernando, Jorge et al, 2023http://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2014242026-05-27T06:46:51Z
dc.title.none.fl_str_mv Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
title Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
spellingShingle Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
Hernando, Jorge
Neuroendocrinologia
Tumors
Factors sexuals en les malalties
Neuroendocrinology
Tumors
Sex factors in disease
title_short Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
title_full Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
title_fullStr Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
title_full_unstemmed Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
title_sort Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
dc.creator.none.fl_str_mv Hernando, Jorge
Roca Herrera, Maria
García Álvarez, Alejandro
Raymond, Eric
Ruszniewski, Philippe
Kulke, Matthew H.
Grande, Enrique
Garcia Carbonero, Rocio
Castellano, Daniel
Salazar, Ramón
Ibrahim, Toni
Teulé Vega, Àlex
Alonso, Vicente
Fazio, Nicola
Valle, Juan W.
Tafuto, Salvatore
Carmona, Ana
Navarro, Victor
Capdevila, Jaume
author Hernando, Jorge
author_facet Hernando, Jorge
Roca Herrera, Maria
García Álvarez, Alejandro
Raymond, Eric
Ruszniewski, Philippe
Kulke, Matthew H.
Grande, Enrique
Garcia Carbonero, Rocio
Castellano, Daniel
Salazar, Ramón
Ibrahim, Toni
Teulé Vega, Àlex
Alonso, Vicente
Fazio, Nicola
Valle, Juan W.
Tafuto, Salvatore
Carmona, Ana
Navarro, Victor
Capdevila, Jaume
author_role author
author2 Roca Herrera, Maria
García Álvarez, Alejandro
Raymond, Eric
Ruszniewski, Philippe
Kulke, Matthew H.
Grande, Enrique
Garcia Carbonero, Rocio
Castellano, Daniel
Salazar, Ramón
Ibrahim, Toni
Teulé Vega, Àlex
Alonso, Vicente
Fazio, Nicola
Valle, Juan W.
Tafuto, Salvatore
Carmona, Ana
Navarro, Victor
Capdevila, Jaume
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Neuroendocrinologia
Tumors
Factors sexuals en les malalties
Neuroendocrinology
Tumors
Sex factors in disease
topic Neuroendocrinologia
Tumors
Factors sexuals en les malalties
Neuroendocrinology
Tumors
Sex factors in disease
description Purpose: There is an increasing interest in the role of sex and gender in cancer pa-tients. The impact of sex differences in oncological systemic therapies is still unknown, and there is a lack of evidence specially in uncommon neoplasms like neuroendocrine tumours (NET). In the present study, we combine the differential toxicities by sex in five published clinical trials with multikinase inhibitors (MKI) in gastroenteropancreatic (GEP) NET.Methods: We performed a pooled univariate analysis of reported toxicity in patients treated in five phase 2 and phase 3 clinical trials with MKI in the GEP NET setting: sunitinib (SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT). Differential toxicities between male and female patients were evaluated considering relationship with study drug and different weights of each trial by random effect adjustment.Results: We found nine toxicities which were more frequent in female patients (leukopenia, alopecia, vomiting, headache, bleeding, nausea, dysgeusia, neutrophil count decreased and dry mouth) and two toxicities being more frequent in male patients (Anal Symptoms and Insomnia). Asthenia and diarrhoea were the only severe (Grade 3-4) toxicities more frequent in female pa-tients.Conclusions: Sex-related differences in toxicity with the MKI treatment require targeted in-formation and individualised management of patients with NET. Differential reporting of toxicity should be promoted when clinical trials are published.(c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY -NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/201424
url https://hdl.handle.net/2445/201424
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1016/j.ejca.2023.04.013
European Journal of Cancer, 2023, vol. 188, p. 39-48
https://doi.org/10.1016/j.ejca.2023.04.013
dc.rights.none.fl_str_mv cc by-nc-nd (c) Hernando, Jorge et al, 2023
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by-nc-nd (c) Hernando, Jorge et al, 2023
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier BV
publisher.none.fl_str_mv Elsevier BV
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416081948409856
score 15.301603

Similares en LA Referencia